Home Cell Cycle CDK inhibitor - JAK inhibitor - FLT3 inhibitor Zotiraciclib For research use only.

Zotiraciclib

Synonyms: SB1317 (TG02)

Zotiraciclib (SB1317; TG02) is a novel small molecule potent CDK/JAK2/FLT3 inhibitor, emerged with potent CDK (IC50 against CDKs 1, 2 and 9 = 9, 5 and 3 nM, respectively), FLT3 (IC50 = 19 nM) and JAK2 (IC50 = 19 nM) potency.

Zotiraciclib Chemical Structure

Zotiraciclib Chemical Structure

CAS No. 937270-47-8

Purity & Quality Control

Batch: S700201 DMSO]15 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.98%
99.98

Zotiraciclib Related Products

Signaling Pathway

CDK Signaling Pathways

CDK Signaling Pathway

Biological Activity

Description Zotiraciclib (SB1317; TG02) is a novel small molecule potent CDK/JAK2/FLT3 inhibitor, emerged with potent CDK (IC50 against CDKs 1, 2 and 9 = 9, 5 and 3 nM, respectively), FLT3 (IC50 = 19 nM) and JAK2 (IC50 = 19 nM) potency.
Features TG02 adopts a slightly different preferred conformation in order to achieve the key interaction with Asp698 when docks into FLT3.
Targets
CDK9 [1] CDK2 [1] CDK1 [1] FLT3 [1] JAK2 [1]
3 nM 5 nM 9 nM 19 nM 19 nM
In vitro
In vitro

SB1317/TG02 inhibits the proliferating of all the cell lines tested including solid tumor cell lines such as colon (HCT-116, COLO205) and prostate (DU145) with IC50 of 33 nM, 72 nM and 140 nM, respectively. SB1317/TG02 potently inhibits the CDK2 biomarker pRb (phospho-Rb, retinoblastoma tumor suppressor protein) in HCT-116, and effects can be detected at the 40 nM with the protein phosphorylation being completely inhibited at 200 nM. SB1317/TG02 is potent against pRb in MV4-11 cells with IC50 of 0.13 μM and also inhibits pFLT3 and pSTAT5 in the same cell line. SB1317/TG02 results in the permeability (Papp) of 26h in the apical to basolateral (Papp,A→B) direction and in the basolateral to apical (Papp,B→A) direction of 28.0 × 10-6 cm/s and 27.4 ×10-6 cm/s, respectively, in the Caco-2 bidirectional permeability assays. SB1317/TG02 is found to be stable with a half-life of 45 min in human liver microsomes (HLM), is moderately stable in DLM (t1/2 = 33 min), and is quite rapidly cleared in MLM (t1/22 = 12 min) and in RLM (t1/2 = 11 min). [1] TG02 most potently inhibits CDK isoforms, inhibits CDK1, CDK2, CDK3, CDK5 and CDK9 with IC50 of 9 nM, 5 nM, 8 nM, 4 nM and 3 nM, respectively. TG02 also inhibits Lck, TYK2, Fyn, JAK2 and FLT3 with IC50 of 11 nM, 14 nM, 15 nM, 19 nM and 19 nM, respectively. TG02 has more potent anti-proliferative effects than SNS-032 in tumor cell lines. TG02 shows a stronger inhibition of the liquid tumor panel with IC50 of 0.13 μM compared with the solid tumor panel with IC50 of 0.30 μM. TG02 (100 nM) induces cell cycle arrest and apoptosis in MV4-11 cells. TG02 inhibits pRb, pFLT3 and pSTAT5 with IC50 of 125 nM, 4.7 μM and 560 nM, respectively, in MV4-11 cells. TG02 inhibits pJAK2 (Y1007/8) and pSTAT3 with IC50 of 63 nM and 53 nM, respectively, in Karpas 1106P. TG02 (300 nM) exposure leads to CDK9 inhibition, followed by G1 phase arrest and apoptotic induction, in HL-60 cells. [2]
Kinase Assay Enzyme Assays
All assays are carried out in 384-well white microtiter plates using the PKLight assay system. TG02 are tested at eight concentrations prepared from 3- or 4-fold serial dilution starting at 10 μM. For CDK2/cyclin A assay, the reaction mixture consist of the following components in 25 μL of assay buffer (50 mM Hepes, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 5 mM BGP, 1 mM DTT, 0.1 mM sodium orthovanadate), 1.4 μg/mL of CDK2/cyclin A complex, 0.5 μM RbING substrate, and 0.5 μM ATP. The mixture is incubated at room temperature for 2 hours. Then 13 μL of PKLight ATP detection reagent is added and the mixture is incubated for 10 min. Luminescence signals are detected on a multilabel plate reader. The other kinase assays are similar, with the following differences in reagents: For FLT3 assays, the mixture contains 2.0 μg/mL FLT3 enzyme, 5 μM poly(Glu,Tyr) substrate, and 4 μM ATP. For JAK2 assays, the reaction contains 0.35 μg/mL JAK2 enzyme, 10 μM poly(Glu,Ala,Tyr) substrate, and 0.15 μM ATP. The analytical software Prism 5.0 is used to generate IC50 values from the data.
Cell Research Cell lines HCT-116, COLO205 and DU145 cell lines
Concentrations ~10 μM
Incubation Time 48 hours
Method

For proliferation assays in 96-well plates, 2×105 cells are seeded in 100 μL of medium and treated the following day with TG02 (in triplicate) at concentrations up to 10 μM for 48 hours. Cell viability is monitored using the CellTiter-96 Aqueous One solution cell proliferation assay. Dose-response curves are plotted to determine IC50 values for TG02 using the XL-fit software.
In Vivo
In vivo

SB1317/TG02 is highly bound to plasma proteins in human, mouse, and dog plasma with PPB ranging between 99.4% to 99.9%. SB1317/TG02 shows oral bioavailability (F) of 4% and 37% in rats and dogs, respectively. SB1317/TG02 (75 mg/kg, orally) shows rapid absorption (tmax = 0.5 h) and a mean Cmax and AUC of 1029 ng/mL and 2523 ng•h/mL, respectively, with a mean terminal half-life of 6.1 hours, and oral bioavailability of 24% in mice. SB1317/TG02 (75 mg/kg po q.d. 3×/week) significantly inhibits the growth of tumors with a mean TGI of 82% in a murine sc xenograft model of human colon cancer (HCT-116), while the lower dose of 50 mg/kg po 3×/week is marginally effective. SB1317/TG02 (75 mg/kg po, 15 mg/kg ip) significantly inhibits the growth of tumors with mean TGIs of 42% and 63% for the oral and ip delivery methods, respectively, in a murine sc xenograft model of human B-cell lymphoma (Ramos). [1] TG02 (60 mg/kg) is selectively retained at supra-therapeutic levels and effectively inhibits CDK2, CDK9 and FLT3 in vivo, causing apoptosis in the tumor tissues, in tumor tissues in MV4-11 tumor-bearing nude mice. TG02 (10 mg/kg, 20 mg/kg and 40 mg/kg) leads to a tumor growth inhibition of 53%, 61% and 113%, respectively, in MV4-11 tumor-bearing nude mice. [2]
Animal Research Animal Models Murine sc xenograft model of human colon cancer (HCT-116)
Dosages 75 mg/kg
Administration orally
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05588141 Recruiting
Brain Tumor|Cancer
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
 May 16 2023 Phase 1|Phase 2
NCT02942264 Completed
Brain Tumor|Astrocytoma|Astroglioma|Glioblastoma|Gliosarcoma
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
 December 14 2016 Phase 1|Phase 2
NCT01204164 Completed
AML|ALL|Blast Crisis|MDS|Multiple Myeloma
Tragara Pharmaceuticals Inc.
 August 2010 Phase 1

Chemical Information & Solubility

Molecular Weight 372.46 Formula

C23H24N4O
CAS No. 937270-47-8 SDF --
Smiles CN1C/C=C/CCOC2=CC(=CC=C2)C3=CC=NC(=NC4=CC=CC(=C4)C1)N3
Storage (From the date of receipt) 3 years-21°C powder

In vitro
Batch:

DMSO : 15 mg/mL ( (40.27 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Zotiraciclib | Zotiraciclib supplier | purchase Zotiraciclib | Zotiraciclib cost | Zotiraciclib manufacturer | order Zotiraciclib | Zotiraciclib distributor